CTRI/2019/08/020820Other未知
A randomized, open label, multi-center, two-treatment, single-period, parallel group, single dose, Pharmacokinetic - Pharmacodynamic study of Leuprorelin Acetate Injectable Suspension 11.25 mg of Daewoong Pharmaceutical Co. Ltd, South Korea with Leuplin depot 3M 11.25 mg S.C. Injection manufactured by Takeda, Japan in male subjects with metastatic prostate cancer undergoing initial therapy under fasting condition - NA
Daewoong Pharmaceutical Co Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- Other
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. Subjects must be able to provide voluntary written informed consent and to follow protocol requirements
- •2. Male subjects aged 18 to 75 years (both inclusive) having Body Mass Index (BMI) at least 17 calculated as weight in kg/height in m2.
- •3. Subjects with histologically/cytologically confirmed prostate cancer.
- •4. Newly diagnosed metastatic prostate cancer patients scheduled to receive their first dose of leuprorelin acetate as a part of their standard of care.
- •5. Subjects with Eastern Cooperative Oncology Group (ECOG) performance status <= 2 (Refer appendix A).
- •6. Acceptable hematology status:
- •a. Hemoglobin >= 9 g/dL
- •b. Absolute neutrophil count (ANC) >= 1500 cells/μL
- •c. Platelet count >= 75,000 cells/μLprior to dosing.
- •7. Acceptable liver function:
- •a. Alanine aminotransferase (ALT) <= 2X upper limit of normal (ULN)
- •b. Aspartate aminotransferase (AST) <= 2X ULN
- •c. Bilirubin < 1.2 mg/dL
- •d. Alkaline phosphatase <= 5X ULN
- •8. Subjects with creatinine clearance >= 60 mL/minute.
- •9. Subjects with HbA1c <= 7 %.
- •10. No history of addiction to any recreational drug or drug dependence or alcohol addiction.
- •11. Subjects who agree to use adequate male contraceptive methods while in the study
- •12. Subjects with life expectancy of > 180 days at the time of screening.
排除标准
- •1. Known hypersensitivity or contraindication to GnRH, GnRH agonist or to any of the components of investigational product.
- •2. History or presence of any uncontrolled debilitating systemic disease (e.g. cardiovascular disease, hypertension, diabetes mellitus etc.).
- •3. Prior orchidectomy, hypophysectomy or adrenalectomy
- •4. Clinical indication of urinary tract obstruction
- •5. Subjects with major surgical procedure (including periodontal) within 28 days of first dose of Investigational Product.
- •6. Subjects with surgical or other non-healing wounds
- •7. Subjects with positive serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or Human Immunodeficiency Virus (HIV)
- •8. Subjects with positive urine screen for drugs of abuse.
- •9. Subjects with positive alcohol breath test.
- •10. Smokers who smoke greater than or equal to 10 cigarettes or equivalent per day
- •11. Participation in any clinical study within 90 days prior to receiving the first dose of Investigational Product.
- •12. Donation of >= 350 mL blood within 90 days prior to receiving the first dose of investigational product for the current study.
- •13. Any other medical condition or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the subject to participate in the study including but not limited to cirrhosis or psychiatric illness/social situations that would limit adherence to study requirements.
- •14. Any other condition(s) which could significantly interfere with Protocol compliance including, but not limited to, dementia, psychosis, cognitive impairment, altered mental status, or other major psychiatric disorder.
- •15. Subjects with known CNS metastasis
- •16. Subjects with history of other malignancies in the last 5 years (except in situ cancer or basal or squamous cell skin cancer).
研究者
相似试验
已完成
1 期
Comparative study of Nilutamide 150 mg tabletCTRI/2018/01/011386Genus Lifesciences Inc40
进行中（未招募）
不适用
Bioequivalence study in advanced renal cell carcinoma patients under fasting condition.CTRI/2022/04/041694Oncogen Pharma Malaysia Sdn Bhd
已完成
4 期
Pharmacokinetic Study of Pazopanib in subjects with Advanced renal cell carcinoma.CTRI/2020/10/028441Torrent Pharmaceuticals Ltd India61
进行中（未招募）
不适用
Bioequivalence study of Olaparib Tablets 150 mg with LYNPARZA�® (Olaparib) tablets 150 mg in male or female patients with ovarian cancer or breast cancer or prostate cancer.CTRI/2021/08/035525atco Pharma Limited
进行中（未招募）
不适用
Multiple dose, steady-state relative bioavailability of Pazopanib 200 mg tablets at a dose of 800 mg (4x200 mg tablets) in subjects with advanced renal cell carcinoma under fasting condition.CTRI/2021/04/032507Oncogen Pharma Malaysia Sdn Bhd15